News
Oncomatryx announces 15m euros funding to conduct clinical trials
Oncomatryx has announced the beginning of a new phase in the development of its tumour microenvironment – targeted antibody drug conjugates (ADCs).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Oncomatryx has announced the beginning of a new phase in the development of its tumour microenvironment – targeted antibody drug conjugates (ADCs).